To evaluate the efficacy and safety of postoperative patient controlled intravenous analgesia (PCIA) with parecoxib sodium combined with morphin and dezocine combined with flurbiprofen axetil after colon carcinoma surgery.

Ninety patients with ASA Ⅰ-Ⅱundergoing elective colon carcinoma surgery were randomly assigned into three groups: parecoxib group (P group), dezocine group (D group) and fentanyl group (F group). They received endotracheal intubation general anesthesia and postoperative PCIA with the background infusion rate 2 ml/h, the bolus infusion rate 2 ml one time and lockout time 15 minutes. The patients in group P were administered parecoxib sodium 40 mg before intubation and 40 mg 12-, 24-, 36-, 48-h after surgery. The PCIA formulation in group P was morphine 20 mg in 100 ml normal saline. The patients in group D were administered dezocine 5 mg before intubation and the PCIA formulation was dezocine 30 mg+ flurbiprofen 200 mg in 100 ml normal saline. The PCIA formulation in group F was fentanyl 1 mg in 100 ml normal saline. VAS score, Ramsay sedation score and the adverse effects were recorded at 30 min (T_30min), 2 h (T_2h), 4 h (T_4h), 12 h (T_12h), 24 h (T_24h), 48 h (T_48h) after surgery. Patient pressing times and patients' satisfactory degree were evaluated 48 hours after surgery.

At T_{30 min} - T_12h time points, the VAS scores in patients of group P and D were lower than those in group F (P﹤0.05). At T_{30 min}-T_4h time points, the Ramsay sedation scores in patients of group P were lower than those in group D and group F (P﹤0.05). The incidences of dizziness during 48 h after surgery in group P and D were significantly lower than those in group F (P﹤0.05).

PCIA with both parecoxib sodium combined with morphin and dezocine combined with flurbiprofen axetil are effective for postoperative pain in patients undergoing colon carcinoma surgery.